Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939534 · ClinicalTrials.gov registry record
Antigen Presentation and Lymphocyte Response in Parkinson's Disease
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 95
- Enrollment target
NCT02939534: Completed study, sponsored by Columbia University.
NCT02939534 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 95 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02939534 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
Study Summary
The way the immune system responds to certain PD-related proteins in PD donors compared to the way it responds in persons without or fewer PD related proteins is not well studied and this study aims to analyze the autoimmune response in each group. The study involves a one time visit involving brief questionnaires and a blood draw of 30 mL (approximately 2 tablespoons) to be collected.
Primary Outcome
Blood samples from PD patients and controls will be processed. The presence of T cell response against the candidate antigens by patient blood-derived peripheral blood mononuclear cells (PBMC) will be assessed using an enzyme-linked immunosorbent spot (ELISPOT) assay.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2015-02 |
| Est. Completion | 2021-02 |
What the finished NCT02939534 record still lists
NCT02939534 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 95 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02939534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02939534 about?
NCT02939534 is a clinical study titled "Antigen Presentation and Lymphocyte Response in Parkinson's Disease". The way the immune system responds to certain PD-related proteins in PD donors compared to the way it responds in persons without or fewer PD related proteins is not well studied and this study aims to analyze the autoimmune response in each group. The study involves a one time visit involving brief...
What is the current status of trial NCT02939534?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2015-02. Estimated completion is 2021-02.
Who is sponsoring clinical trial NCT02939534?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia